Clinical Reasoning: An 80-Year-Old Woman With a Homonymous Hemianopsia

Deena Tajfirouz, MD, John J. Chen, MD, PhD, and M. Tariq Bhatti, MD

Neurology® 2022;99:713-717. doi:10.1212/WNL.0000000000201175

Abstract

An 80-year-old woman who was experiencing visual symptoms for 2 years was found to have a left homonymous hemianopsia (HH). On further evaluation the following month, she was noted to have simultanagnosia and alexia. MRI of the brain did not reveal a structural etiology for the symptoms. [18F]-fluorodeoxyglucose (FDG) PET-CT was performed to aid in the diagnostic investigation. This case of posterior cortical atrophy highlights the differential diagnosis of a HH in the absence of a structural lesion on MRI and the role of FDG PET-CT imaging in such patients.

Section 1

An 80-year-old woman with hypertension, hyperlipidemia, and type 2 diabetes mellitus reported 2 years of progressive difficulty reading and loss of depth perception. More recently, she stopped driving and was running into objects while walking. Initial evaluation by a local ophthalmologist identified bilateral cataracts resulting in surgical extraction, which did not improve the visual symptoms. Automated visual field (AVF) testing demonstrated a left homonymous hemianopsia (HH). Routine laboratory evaluation showed normal blood counts and chemistries. The patient was referred to a neurologist, and a normal neurologic examination was noted. A brain MRI with contrast showed normal age-related changes, but specifically, there was no evidence of a prior stroke, restricted diffusion on the diffusion-weighted images, tumor, abnormal posterior cortical asymmetry, or enhancement. The patient was referred to neuro-ophthalmology for further evaluation.

On our evaluation, visual acuity was 20/30 in each eye. She identified only 1 of 13 plates in each eye from the Ishihara pseudochromatic book. Confrontation testing was inconsistent to finger counting, but there was a nasal defect in the right eye and a temporal defect in the left eye. Pupils were equal with normal light reflexes and no relative afferent pupillary defect. Slitlamp examination showed centered posterior chamber intraocular lenses with normal intraocular pressure. The optic disc, macula, and retina appeared normal in each eye. Repeat AVF testing confirmed the left HH (Figure 1A).

Questions for Consideration:
1. Where is the lesion responsible for the visual field defect?
2. What is the cause of the decreased color vision?
3. What is the differential diagnosis for a HH with a negative MRI?
**Glossary**

AVF = Automated visual field; CJD = Creutzfeldt-Jacob disease; FDG = fluorodeoxyglucose; HH = homonymous hemianopsia; PCA = posterior cortical atrophy.

---

**Figure 1** Interpretation of Humphrey Visual Field Test Printout

(A) 24-2 Humphrey analyzer (Carl Zeiss Meditec AG, Dublin, CA). There is a left homonymous hemianopsia. Annotations highlight the various metrics needed to interpret the results. (B) Approach to automated perimetry interpretation.

---

(A) 24-2 Humphrey analyzer (Carl Zeiss Meditec AG, Dublin, CA). There is a left homonymous hemianopsia. Annotations highlight the various metrics needed to interpret the results. (B) Approach to automated perimetry interpretation.
Section 2

The pattern of a visual field defect can often determine the anatomic location of the lesion (Figure 2). In general, the following characteristics of a visual field defect should be noted: monocular or binocular, homonymous or heteronymous, complete or incomplete, and incongruous or congruous. Historically, a congruent HH was considered to originate from a lesion involving the occipital lobe, but this paradigm has been shown not to be a reliable localizing sign. Therefore, in our patient, the presence of a left HH localizes the site of the lesion to anywhere along the right retrochiasmal visual pathway (i.e., right optic tract, optic radiations, or occipital lobe).

AVF is designed to detect visual field defects by projecting lights of different brightness, size, and location while the patient fixates at the center of a hemispherical bowl. Typically, the central 24–30° of vision is tested with a target size of III (4 mm²) stimulus. These stimuli are algorithmically planned to decrease patient anticipation and increase reliability. For the test to be valid, the patient must be able to reliably participate and complete the test. Patient factors such as familiarity with the test (i.e., learning curve), age, cognition, and physical abilities affect reliability. Fixation losses, false-positive responses (a positive response but there is no target displayed), and false-negative responses (failure to signal at a target that was previously seen in the same location) are metrics measured and displayed on the printout that determine the reliability of the test. Fixation losses should be less than 20% and false-negative errors and false-positive errors less than 20%–30% for the test to be reliable (Figure 1B).

Any visual field defect should be interpreted within the context of other clinical signs and symptoms. The Ishihara pseudochromatic color plates are often used clinically to screen for dyschromatopsia by displaying a symbol (number or geometric figure) composed of colored dots against a background of differently colored dots; however, they can also be used as a screening tool for simultanagnosia. Patients with simultanagnosia are unable to perceive more than a single image at a time and often have trouble depicting the numbers from the background without actual impairment in color vision because of the inherent nature of the test. Further testing was notable for alexia and inability to name single objects in overlapping figures. Our patient’s difficulty with the Ishihara color plates was likely because of simultanagnosia because she did not have a history of congenital color blindness and there was no evidence of optic neuropathy or retinopathy on examination. She scored 27 of 38 on the Kokmen Short Test of Mental Status, by obtaining 8 of 8 points in Orientation, 6 of 7 in Attention, 4 of 4 in Registration, 0 of 4 in Calculation, 2 of 3 in Similarities, 1 of 4 in Construction, 4 of 4 in Knowledge, and 2 of 4 in Recall.

An HH without a structural lesion on brain MRI has a short but important differential diagnosis that includes the Heidenhain variant of Creutzfeldt-Jacob disease (CJD), posterior cortical atrophy (PCA) syndrome, nonketotic hyperglycemia, seizures, subtle occipital ischemia, or a functional visual disorder. In our patient, the duration of symptoms and lack of diffusion restriction on the brain MRI made CJD unlikely. Normal laboratory evaluation and the progressive nature of the symptoms made hyperglycemia or a vascular etiology unlikely. The history and examination findings were not consistent with seizures or a functional visual disorder.

Question for Consideration:
1. What further testing would you perform?
Section 3

[18F]-fluorodeoxyglucose (FDG) PET-CT showed asymmetric moderate hypometabolism involving the right posterior cerebral hemisphere in a pattern consistent with PCA (eFigure 1, links.lww.com/WNL/C290). Studies have shown that FDG PET-CT, which measures functionality, is more sensitive and specific when evaluating patients with mild cognitive impairment compared with MRI, which is a structural measurement.7,8 She was referred to neurology for management but declined further neuropsychiatric testing or initiation of treatment.

Discussion

PCA is a rare, progressive, neurodegenerative syndrome that affects the posterior cortices resulting in visual dysfunction early in the disease.9 The disease process may initially affect parietal, occipital, or occipitotemporal regions; therefore, patients can present with a wide range of visual symptoms affecting higher order visual function while sparing anterograde memory, language, executive functions, and personality.10,11 PCA typically presents in the fifth and sixth decades of life, and as the disease progresses, patients develop dysfunction of other cognitive domains. The most common etiology of PCA syndrome is Alzheimer disease pathology; however, it can also be seen with other underlying pathologies such as dementia with Lewy body, corticobasal degeneration, prion disease, and subcortical gliosis.9,12-14

The initial symptoms of PCA can be visuospatial-visuoperceptual impairments such as alexia, homonymous visual field deficits, features of Balint syndrome (simultanagnosia, oculomotor apraxia, optic ataxia, environmental agnosia) or Gerstmann syndrome (acalculia, agraphia, finger agnosia, left/right disorientation).15 Patients with PCA syndrome commonly present with reading difficulties while simultanagnosia and homonymous visual field defects are also common findings in the initial evaluation. Homonymous visual field defects have been reported to be present in up to 60% of patients, highlighting the importance of AVF testing and cognitive assessment in suspected cases.13

Our patient with HH, alexia, and simultanagnosia met diagnostic criteria for PCA syndrome.12 This case highlights the importance of considering neurodegenerative disease when a patient older than 45 years presents with a reproducible HH and negative findings on MRI.

Study Funding

No targeted funding reported.

Disclosure

The authors reported no relevant disclosures. Go to Neurology.org/N for full disclosures.

Publication History

Received by Neurology March 15, 2022. Accepted in final form July 14, 2022. Submitted and externally peer-reviewed. The handling editor was Roy Strowd III, MD, Med, MS.

Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deena Tajfirouz, MD</td>
<td>Department of Ophthalmology, Mayo Clinic College of Medicine</td>
<td>Drafting/review of the manuscript for content, including medical writing for content; major role in the acquisition of data; analysis or interpretation of data</td>
</tr>
</tbody>
</table>
References


Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>John J. Chen, MD, PhD</td>
<td>Department of Ophthalmology, Mayo Clinic College of Medicine; Mayo Clinic College of Medicine</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content</td>
</tr>
<tr>
<td>M. Tariq Bhatti, MD</td>
<td>Department of Ophthalmology, Mayo Clinic College of Medicine; Department of Neurology, Mayo Clinic College of Medicine</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data</td>
</tr>
</tbody>
</table>

Neurology® Genetics is an online-only, open-access journal publishing peer-reviewed reports in the area of neurogenetics that elucidate the role of genetic and epigenetic variations in diseases and biological traits of the central and peripheral nervous systems. The journal’s Impact Factor is 3.485. Access Neurology: Genetics at NG.Neurology.org.

Neurology® Neuroimmunology & Neuroinflammation is an online-only, open-access journal with rigorously peer-reviewed reports of research in this area affecting the full range of neurologic diseases. Articles, editorials, and reviews aim to facilitate basic and translational research, along with enhancing patient care. The journal’s Impact Factor is 8.485. Access Neurology: Neuroimmunology & Neuroinflammation at NN.Neurology.org.

Subspecialty Alerts by E-mail!

Customize your online journal experience by signing up for e-mail alerts related to your subspecialty or area of interest. Access this free service by clicking on the “My Alerts” link on the home page. An extensive list of subspecialties, methods, and study design choices will be available for you to choose from—allowing you priority alerts to cutting-edge research in your field!
Clinical Reasoning: An 80-Year-Old Woman With a Homonymous Hemianopsia
Deena Tajfirouz, John J. Chen and M. Tariq Bhatti
Neurology 2022;99:713-717 Published Online before print August 29, 2022
DOI 10.1212/WNL.0000000000201175

This information is current as of August 29, 2022